Buscar
Mostrando ítems 1-10 de 25670
Expressão de HER-1 e HER-2 totais e fosforilados em queilite actínica e carcinoma epidermóide de lábio inferior
(Universidade Estadual Paulista (Unesp), 2010-06-30)
A queilite actínica (QA) é uma lesão multifocal que acomete o vermelhão do lábio com potencial de malignização para carcinoma epidermóide (CE). O receptor para o fator de crescimento epidermal (EGFR) é membro da família ...
Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling
(Oxford Univ Press Inc, 2015-04-17)
Background: Several treatment strategies target the human epidermal growth factor receptor 2 (HER2) in breast carcinomas, including monoclonal antibodies directed against HER2?s extracellular domain (ECD) and small molecule ...
Os her??is ?? margem: um estudo sobre a po??tica dos anti-her??is em meteorango kid-her??i inergal??ctico e superoutro
(Faculdade de Comunica????oMestrado em Comunica????o e Cultura Contempor??neasUFBAbrasil, 2018-01-23)
Expressão de HER-1 e HER-2 totais e fosforilados em queilite actínica e carcinoma epidermóide de lábio inferior
(Universidade Estadual Paulista (UNESP), 2014)
Expressão de HER-1 e HER-2 totais e fosforilados em queilite actínica e carcinoma epidermóide de lábio inferior
(Universidade Estadual Paulista (Unesp), 2014)
HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors
(Ivyspring Int Publ, 2017-01-01)
Persistent HPV infection alone is not sufficient for cervical cancer development, which requires additional molecular alterations for tumor progression and metastasis ultimately leading to a lethal disease. In this study, ...
Piggybac transposon-based production of anti-HER2 CAR T cell
(Fiocruz/Instituto de Tecnologia em Imunobiológicos, 2022)
Hamlet: A Aurora do Anti-Her??i Moderno
(NEF da UEFS, 1997)
Recent treatment advances in HER2-positive metastatic breast cancer: a clinical approach
(2012-05)
The use of targeted therapy directed against HER2 is currently the standard of care in patients with metastatic HER2-positive breast cancer. The combination of trastuzumab with a taxane as first-line treatment in HER2-positive ...